[go: up one dir, main page]

FR12C0072I2 - POLYVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND PROTEIN - Google Patents

POLYVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND PROTEIN

Info

Publication number
FR12C0072I2
FR12C0072I2 FR12C0072C FR12C0072C FR12C0072I2 FR 12C0072 I2 FR12C0072 I2 FR 12C0072I2 FR 12C0072 C FR12C0072 C FR 12C0072C FR 12C0072 C FR12C0072 C FR 12C0072C FR 12C0072 I2 FR12C0072 I2 FR 12C0072I2
Authority
FR
France
Prior art keywords
polysaccharide
conjugate
protein
vaccine prepared
meningococcal vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0072C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0072(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of FR12C0072I1 publication Critical patent/FR12C0072I1/fr
Application granted granted Critical
Publication of FR12C0072I2 publication Critical patent/FR12C0072I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR12C0072C 2001-01-23 2012-11-29 POLYVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND PROTEIN Active FR12C0072I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
PCT/US2002/001963 WO2002058737A2 (en) 2001-01-23 2002-01-22 Multivalent meningococcal polysaccharide-protein conjugate vaccine

Publications (2)

Publication Number Publication Date
FR12C0072I1 FR12C0072I1 (en) 2013-01-04
FR12C0072I2 true FR12C0072I2 (en) 2013-11-01

Family

ID=23001755

Family Applications (3)

Application Number Title Priority Date Filing Date
FR12C0072C Active FR12C0072I2 (en) 2001-01-23 2012-11-29 POLYVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND PROTEIN
FR15C0094C Active FR15C0094I2 (en) 2001-01-23 2015-12-21 TRI- OR TETRAVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND CRM197
FR22C1001C Active FR22C1001I2 (en) 2001-01-23 2022-01-06 PROTEIN-POLYSACCHARIDE CONJUGATE VACCINE FOR POLYVALENT MENINGOCOCCAL DISEASE

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR15C0094C Active FR15C0094I2 (en) 2001-01-23 2015-12-21 TRI- OR TETRAVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND CRM197
FR22C1001C Active FR22C1001I2 (en) 2001-01-23 2022-01-06 PROTEIN-POLYSACCHARIDE CONJUGATE VACCINE FOR POLYVALENT MENINGOCOCCAL DISEASE

Country Status (38)

Country Link
US (9) US8722062B2 (en)
EP (3) EP2957300B1 (en)
JP (6) JP2005504718A (en)
KR (2) KR100947751B1 (en)
CN (1) CN100556459C (en)
AP (1) AP1897A (en)
AU (2) AU2007216743A1 (en)
BE (3) BE2012C050I2 (en)
BR (1) BRPI0206672B8 (en)
CA (1) CA2435681C (en)
CR (1) CR7035A (en)
CY (2) CY1113072T1 (en)
DK (2) DK2332581T3 (en)
EA (1) EA006947B1 (en)
EC (1) ECSP034701A (en)
ES (3) ES2388848T3 (en)
FR (3) FR12C0072I2 (en)
GE (1) GEP20053691B (en)
HR (1) HRP20030598B1 (en)
HU (2) HU230490B1 (en)
IL (3) IL157060A0 (en)
IS (1) IS6881A (en)
LT (1) LT5177B (en)
LU (1) LU92108I2 (en)
LV (1) LV13128B (en)
MX (2) MXPA03006561A (en)
NO (1) NO20033816L (en)
NZ (2) NZ622900A (en)
OA (1) OA12590A (en)
PL (1) PL226184B1 (en)
PT (2) PT1355673E (en)
RO (1) RO122761B1 (en)
SI (1) SI21352A (en)
TN (1) TNSN03041A1 (en)
UA (1) UA92579C2 (en)
WO (1) WO2002058737A2 (en)
YU (1) YU66103A (en)
ZA (1) ZA200306176B (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
MXPA04011249A (en) * 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004033623A2 (en) * 2002-05-16 2004-04-22 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
CN1738642A (en) * 2002-11-14 2006-02-22 血清疫苗研究生产中心芬雷学院 Method of obtaining conjugate vaccines and vaccine compositions containing same
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
BRPI0408167B1 (en) * 2003-03-07 2014-10-21 Wyeth Corp POLYESACARIDE PROTEIN ADESINE VEHICLE CONJUGATES FOR STAPHILOCOCIC SURFACE FOR IMMUNIZATION AGAINST NOSOCOMIAL INFECTIONS
CN1819843A (en) * 2003-05-07 2006-08-16 安万特巴斯德公司 Method of enhanced immunogenicity to meningococcal vaccination
DE602004022286D1 (en) * 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS BASED ON BIODEGRADABLE MICRO PARTICLES CONTAINING A DIPHTHERIA AND TETANO TOXOID
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
JP4918356B2 (en) * 2003-06-23 2012-04-18 バクスター・インターナショナル・インコーポレイテッド Y group meningococcal vaccine and their meningococcal combination vaccine
AU2004277758A1 (en) * 2003-10-02 2005-04-14 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP1740217B1 (en) * 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20060088554A1 (en) * 2004-08-30 2006-04-27 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
AU2005286798A1 (en) * 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
SI1896063T1 (en) 2005-06-27 2012-03-30 Glaxosmithkline Biolog Sa Immunogenic composition
BRPI0615420A2 (en) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic multiple vaccination including serogroup c meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
KR20150038626A (en) * 2006-03-17 2015-04-08 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US20080026002A1 (en) * 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
RU2009149359A (en) 2007-06-04 2011-07-20 Новартис АГ (CH) COMPOSITION OF VACCINES AGAINST Meningitis
MX340096B (en) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Meningococcal vaccine formulations.
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
EP2608805B1 (en) 2010-08-23 2017-07-05 Wyeth LLC STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
ES2744471T3 (en) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Bactericidal antibody assays to assess immunogenesis and potency of meningococcal capsular saccharide vaccines
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
JP6191082B2 (en) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Combination vaccine with lower dose of antigen and / or adjuvant
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
RU2636350C2 (en) 2011-11-07 2017-11-22 Новартис Аг MOLECULE CONTAINING spr0096 AND spr2021
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
CN102660602B (en) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 Method for rapidly purifying bacteria capsular polysaccharide
JP2015518845A (en) 2012-05-22 2015-07-06 ノバルティス アーゲー Neisseria meningitidis serogroup X conjugate
SI3421051T1 (en) * 2012-08-16 2020-08-31 Pfizer Inc. Glycoconjugation processes and compositions
MX2015002717A (en) 2012-09-06 2015-05-15 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p.
CN102861326A (en) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 Epidemic encephalitis polysaccharide-protein conjugated vaccine and preparation method thereof
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
SI2976101T1 (en) * 2013-03-18 2021-01-29 Glaxosmithkline Biologicals S.A. Method of treatment
CA2918076A1 (en) 2013-07-11 2015-01-15 Novartis Ag Site-specific chemoenzymatic protein modifications
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2865485T3 (en) 2014-05-24 2021-10-15 Biological E Ltd New semi-synthetic meningococcal conjugate vaccine
CN107249626A (en) 2015-02-19 2017-10-13 辉瑞大药厂 Neisseria meningitidis compositions and methods thereof
US20180064830A1 (en) 2015-02-20 2018-03-08 Bayer Healthcare Llc Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (en) 2015-03-25 2016-01-29 한국기계연구원 Magnesium alloy having improved corrosion resistance and method for manufacturing magnesium alloy member using the same
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
PL3397319T3 (en) 2015-12-30 2025-03-24 Ascendis Pharma A/S AUTOMATIC INJECTOR WITH CARTRIDGE LOCKING SYSTEM
KR102204927B1 (en) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) Method for quality evaluation of capsular polysacchride-protein conjugate vaccine
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
PE20191107A1 (en) 2017-01-31 2019-08-26 Pfizer COMPOSITIONS OF NEISSERIA MENINGITIDIS AND RESPECTIVE METHODS
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
US12119099B2 (en) 2018-09-12 2024-10-15 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
WO2020168146A1 (en) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae
CN110903388B (en) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 Method for removing cross reaction of meningococcal antiserum
JP2023506539A (en) 2019-12-17 2023-02-16 ９２８６－３６２０ ケベック インコーポレイテッド Oral delivery system based on in situ formation of protein/polysaccharide coacervates
KR102610292B1 (en) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) A method of preparing a conjugate of Streptococcus pneumoniae polysaccharide and carrier protein
MX2023009728A (en) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Meningococcal b recombinant vaccine.
IL316130A (en) 2022-04-11 2024-12-01 Sanofi Pasteur Inc Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (en) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 Adjuvanted immunogenic composition against neisseria meningitidis b
WO2025034954A1 (en) 2023-08-09 2025-02-13 Bayer Healthcare Llc Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
EP0109350B1 (en) 1982-11-10 1991-10-16 Mitsubishi Jukogyo Kabushiki Kaisha Nickel-chromium alloy
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
ATE38064T1 (en) 1985-04-17 1988-11-15 Akzo Nv PROCEDURE FOR INSTALLING A WAYMARKER COMPOSITION.
DE3518706A1 (en) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe METHOD FOR PRODUCING MOLDED BODIES WITH IMPROVED ISOTROPICAL PROPERTIES
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
WO1990006696A2 (en) * 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69231663T2 (en) * 1991-03-12 2001-08-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services POLYSACCHARIDE PROTEIN CONJUGATE
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
CZ28694A3 (en) 1991-08-16 1994-05-18 Merck & Co Inc Process for preparing capsular polysaccharide free of lipid and endotoxin
US5422427A (en) * 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (en) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT.
DK0835663T3 (en) * 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Combined vaccines comprising Hepatitis B surface antigen and other antigens
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
JP4097691B2 (en) 1992-08-31 2008-06-11 バクスター、ヘルスケア、ソシエテ、アノニム Vaccine against group C meningococcus
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
IL122431A0 (en) 1995-06-07 1998-06-15 Smithkline Beecham Biolog Combined vaccine comprising a polysaccharide antigen conjugated to a carrier protein
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
NZ312132A (en) 1995-06-23 1999-04-29 Smithkline Beecham Biolog A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
ES2335557T3 (en) * 1997-01-21 2010-03-29 Sanofi Pasteur CONJUGATES OF PEPTIDO-POLISACARIDO.
WO1998032873A1 (en) 1997-01-24 1998-07-30 Schweiz. Serum- & Impfinstitut Bern New method for isolating polysaccharides
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
JP2002504096A (en) 1997-04-24 2002-02-05 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン Conjugation of unmodified proteins with haloacyl or dihalacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
EP1849860B1 (en) 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin
WO1998058670A1 (en) * 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CA2316975C (en) * 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
BRPI0007936B8 (en) 1999-02-01 2021-05-25 Eisai Co Ltd compound, immunological adjuvant formulation, and vaccine formulation.
MY125387A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4948731B2 (en) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Compositions and methods for stabilizing biological molecules during lyophilization
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
ATE534402T1 (en) 2000-06-29 2011-12-15 Smithkline Beecham Biolog MULTIVALENT VACCINE COMPOSITION
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
FR12C0072I1 (en) 2013-01-04
EP2332581A1 (en) 2011-06-15
US9844601B2 (en) 2017-12-19
EA006947B1 (en) 2006-06-30
KR20030084913A (en) 2003-11-01
HU230490B1 (en) 2016-08-29
DK1355673T3 (en) 2012-09-17
MXPA03006561A (en) 2004-10-15
US8999354B2 (en) 2015-04-07
US8741314B2 (en) 2014-06-03
EP2332581B1 (en) 2015-07-01
ECSP034701A (en) 2003-10-28
US20150174259A1 (en) 2015-06-25
LV13128B (en) 2004-07-20
NO20033816L (en) 2003-09-11
US8734813B2 (en) 2014-05-27
CA2435681A1 (en) 2002-08-01
GEP20053691B (en) 2005-12-12
CN100556459C (en) 2009-11-04
ES2892316T3 (en) 2022-02-03
ES2388848T3 (en) 2012-10-19
TNSN03041A1 (en) 2005-12-23
KR100947751B1 (en) 2010-03-18
UA92579C2 (en) 2010-11-25
CA2435681C (en) 2011-06-21
YU66103A (en) 2006-05-25
WO2002058737A2 (en) 2002-08-01
OA12590A (en) 2006-06-08
LT2003071A (en) 2004-08-25
IL157060A0 (en) 2004-02-08
JP2014043475A (en) 2014-03-13
US20130224241A1 (en) 2013-08-29
US20030068336A1 (en) 2003-04-10
LU92108I9 (en) 2019-01-15
EP1355673A2 (en) 2003-10-29
HRP20030598A2 (en) 2005-06-30
BR0206672A (en) 2005-05-10
US10617766B2 (en) 2020-04-14
KR20090029857A (en) 2009-03-23
AP2003002829A0 (en) 2003-09-30
DK2332581T3 (en) 2015-10-05
NZ622900A (en) 2015-11-27
FR22C1001I1 (en) 2022-02-18
JP2016128526A (en) 2016-07-14
PL373710A1 (en) 2005-09-05
EA200300827A1 (en) 2004-06-24
NZ602682A (en) 2014-05-30
BRPI0206672B1 (en) 2018-11-06
IS6881A (en) 2003-07-22
FR15C0094I1 (en) 2016-01-22
PT2332581E (en) 2015-10-16
MX341760B (en) 2016-09-02
CY2012030I1 (en) 2015-08-05
JP2005504718A (en) 2005-02-17
SI21352A (en) 2004-06-30
HUS1600040I1 (en) 2019-05-28
EP1355673B1 (en) 2012-05-30
US20140308311A1 (en) 2014-10-16
RO122761B1 (en) 2010-01-29
FR22C1001I2 (en) 2025-02-07
BE2012C050I2 (en) 2021-03-23
AP1897A (en) 2008-10-10
IL225522A0 (en) 2013-06-27
FR15C0094I2 (en) 2017-05-19
CY2012030I2 (en) 2016-08-31
IL157060A (en) 2013-04-30
IL225522A (en) 2016-04-21
US10143757B2 (en) 2018-12-04
LU92108I2 (en) 2013-01-29
PL226184B1 (en) 2017-06-30
EP2957300A2 (en) 2015-12-23
JP2014043474A (en) 2014-03-13
CR7035A (en) 2008-11-25
ZA200306176B (en) 2005-03-30
HUP0302999A2 (en) 2003-12-29
HUP0302999A3 (en) 2011-05-30
BRPI0206672B8 (en) 2021-05-25
EP2957300B1 (en) 2021-07-14
US20190060475A1 (en) 2019-02-28
NO20033816D0 (en) 2003-08-27
US9173955B2 (en) 2015-11-03
BE2022C502I2 (en) 2023-04-12
KR100947757B1 (en) 2010-03-18
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
US20130216571A1 (en) 2013-08-22
AU2010219288A1 (en) 2010-09-23
CY1113072T1 (en) 2015-08-05
HRP20030598B1 (en) 2013-05-31
PT1355673E (en) 2012-08-31
JP2011140522A (en) 2011-07-21
JP2014065745A (en) 2014-04-17
US20160000928A1 (en) 2016-01-07
EP2957300A3 (en) 2016-03-30
ES2544979T3 (en) 2015-09-07
JP5795721B2 (en) 2015-10-14
AU2007216743A1 (en) 2007-10-04
CN1610560A (en) 2005-04-27
WO2002058737A3 (en) 2003-05-22
BE2015C077I2 (en) 2021-02-04
US8722062B2 (en) 2014-05-13
LT5177B (en) 2004-11-25

Similar Documents

Publication Publication Date Title
FR12C0072I2 (en) POLYVALENT MENINGOCOCCAL VACCINE PREPARED WITH A CONJUGATE OF POLYSACCHARIDE AND PROTEIN
HK1204574A1 (en) Multivalent meningococcal derivatized polysaccharide protein conjugates and corresponding vaccines
HK1195512A1 (en) Polysaccharide protein conjugate vaccines
MA27049A1 (en) 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
HUP0103100A3 (en) Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
DK1221919T3 (en) Ophthalmic drug administration device
BR0009163A (en) Vaccine
EP1575500A4 (en) MESOTHELIN VACCINES AND MODEL SYSTEMS
EP1529054A4 (en) THERAPEUTIC PROTEIN AND TREATMENTS
NO20004907D0 (en) Aqueous emulsion and preparation thereof
FR2866884B1 (en) ARYL-AND HETEROARYL-PIPERIDINECARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP1421185A4 (en) RAPID STERILIZATION AND PREPARATION OF VACCINE
EP1307130A4 (en) VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS
DZ3219A1 (en) VACCINE
FR2843964B1 (en) DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
MA28845B1 (en) N- (1H-INDOLYL) -IH-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP1423141A4 (en) VACCINE
EP1450752A4 (en) MULTIVALENT STREPTOCOCCULAR VACCINE COMPOSITIONS AND APPLICATION METHODS
EP1495118A4 (en) STRONG EXPRESSION OF IMMUNOGENIC PROTEINS IN THE PLASTICES OF HIGHER PLANTS
FR2850377B1 (en) ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
MA27233A1 (en) PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2809731B1 (en) 1,4-DIAZABICYCLO- [3.2.2] NONANE-PHEYLISOXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2873690B1 (en) OXOPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2819810B1 (en) NON-GLYCOSYL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
EP1389043A4 (en) FOOT AND MOUTH DISEASE VACCINE